135 related articles for article (PubMed ID: 1710871)
21. [Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer].
Ushiyama T; Ihara H; Kurita Y; Kageyama S; Ueda D; Mugiya S; Yamaguchi Y; Nakano M; Suzuki K; Kawabe K
Hinyokika Kiyo; 1993 Dec; 39(12):1139-44. PubMed ID: 8285162
[TBL] [Abstract][Full Text] [Related]
22. [Induction therapy with CDDP and ADM for stage D prostatic cancer and its clinical response].
Yushita Y; Sakai H; Nomata K; Suzu H; Minami Y; Ogawa S; Yamashita S; Kanetake H; Saito Y
Hinyokika Kiyo; 1990 Dec; 36(12):1415-21. PubMed ID: 2075879
[TBL] [Abstract][Full Text] [Related]
23. [A case of giant prostate cancer].
Fujimoto Y; Yamaha M; Maeda S; Takeuchi T; Ito Y; Kuriyama M; Ban Y; Nishiura T
Hinyokika Kiyo; 1984 Jul; 30(7):925-30. PubMed ID: 6542303
[TBL] [Abstract][Full Text] [Related]
24. [Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)].
Kondo I; Miura T; Fujii H; Harada M; Fukushima S; Kubota Y; Hosaka M
Hinyokika Kiyo; 1996 Mar; 42(3):201-6. PubMed ID: 8619389
[TBL] [Abstract][Full Text] [Related]
25. [Endocrine chemotherapy for prostatic cancer].
Maekawa T; Kashihara N; Tsujita M; Morikawa Y; Hayahara N; Nishijima T; Ezaki K; Senju M; Iritani M; Yamaguchi M
Hinyokika Kiyo; 1994 Jun; 40(6):555-61. PubMed ID: 7521118
[TBL] [Abstract][Full Text] [Related]
26. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
[TBL] [Abstract][Full Text] [Related]
27. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
28. [Clinical study of endocrine therapy in stage B and C prostate cancer].
Uei T; Okazaki H; Nakamura T; Katou N; Suzuki K; Yamanaka H
Hinyokika Kiyo; 2003 Nov; 49(11):639-43. PubMed ID: 14719450
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
30. [Clinical study of prostate cancer--statistical analysis in the last 10 years].
Yamamoto N; Shimabukuro T; Matsuyama H; Yoshihiro S; Mitsui H; Sakatoku J
Hinyokika Kiyo; 1991 Jul; 37(7):705-10. PubMed ID: 1927770
[TBL] [Abstract][Full Text] [Related]
31. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
32. Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience.
Zincke H
Semin Urol; 1990 Aug; 8(3):175-83. PubMed ID: 2399386
[No Abstract] [Full Text] [Related]
33. [Combined hormone and chemotherapy for the patients with advanced prostate cancer].
Uekado Y; Hirano A; Inagaki T; Hiroi A; Watanabe T
Gan To Kagaku Ryoho; 1995 Jul; 22(8):1041-5. PubMed ID: 7611755
[TBL] [Abstract][Full Text] [Related]
34. [Correlation between histologic grading and prognosis of prostatic cancer--comparing the grading system of the Japanese general rules of prostatic cancer with Gleason's grading].
Hioki T; Sugimura Y; Sakurai M; Hayashi N; Tochigi H; Kawamura J; Yatani R
Hinyokika Kiyo; 1990 Aug; 36(8):921-6. PubMed ID: 2239593
[TBL] [Abstract][Full Text] [Related]
35. [Clinical study on prostatic cancer patients].
Yasumoto R; Asakawa M
Hinyokika Kiyo; 1989 Jan; 35(1):65-9. PubMed ID: 2729021
[TBL] [Abstract][Full Text] [Related]
36. Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology.
Vesalainen S; Lipponen P; Nordling S; Talja M; Syrjänen K
Anticancer Res; 1995; 15(2):569-73. PubMed ID: 7763039
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of newly diagnosed stage D2 prostatic carcinoma with hormonal therapy alone, or chemotherapy agents in combination with hormones].
Fujii A; Oka N; Miyasaki S; Higuchi A; Tomioka O; Morishita S; Yamanaka K; Itoh N; Okamoto Y; Tanaka H
Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1656-63. PubMed ID: 1722834
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
Soloway MS
Am J Clin Oncol; 1988; 11 Suppl 1():S29-32. PubMed ID: 3133944
[TBL] [Abstract][Full Text] [Related]
39. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
40. [Clinical studies on endocrine therapy for prostatic carcinoma (4): Initial response to endocrine therapy and prognosis].
Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Ohshima H; Takeuchi H; Yoshida O; Okada K; Saito Y
Hinyokika Kiyo; 1991 Nov; 37(11):1505-10. PubMed ID: 1767773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
